Vimarsana
Biggest News Aggregation in the World

Page 5 - For Grade News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from For Grade. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In For Grade Today - Breaking & Trending Today

Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting - Vimarsana News

Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for...

U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer - Vimarsana News

U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for...

US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer - Vimarsana News

US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer

/PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) for...

Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology - Vimarsana News

Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology

The benefit of adjuvant Verzenio in combination with endocrine therapy continues to deepen with additional follow-up, now demonstrating an absolut...

Lilly Announces Details of Presentations at ESMO Congress 2022 - Vimarsana News

Lilly Announces Details of Presentations at ESMO Congress 2022

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib) and Retevmo® (selpercatinib) will be...